By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ApoCell said Wednesday that it has been awarded a $2.9 million contract by SAIC-Frederick to develop and deliver 12 alpha prototype units of ApoCell's circulating tumor cell detection system.

The order from SAIC-Frederick, in support of the National Cancer Institute, is the first commercial order for the system called ApoStream. ApoCell said it expects to deliver the units to SAIC-Frederick in early 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.